# OnCo record epsilogen (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/epsilogen/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "epsilogen" ;
  schema:name "Epsilogen"@en ;
  schema:description "Epsilogen develops antibody medicines of the IgE class, a type of antibody normally involved in allergy, to rally the immune system against cancer. Its lead medicine, MOv18 IgE, is in an early trial in ovarian cancer that has stopped responding to platinum chemotherapy."@en ;
  schema:url <https://onco.cc/companies/epsilogen/>, <https://epsilogen.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://epsilogen.com/>, <https://clinicaltrials.gov/study/NCT06547840>, <https://epsilogen.com/arpa-h-backs-advancement-of-engineered-iga-antibody-therapeutics-toward-clinical-development/> ;
  schema:addressCountry "GB" ;
  onco:cancers <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/folr1/> .